CTI Capital

Wattio is a developer of smart home technology that offers a comprehensive range of gadgets and software aimed at enhancing comfort, energy efficiency, and security within the home. The company has created an in-house secure technology platform that integrates all hardware and software components, allowing for flexibility and scalability. Its central hub, a Linux-based minicomputer, enables users to connect additional devices and third-party hardware seamlessly. Wattio's all-in-one solution simplifies home management by centralizing control over electricity, energy usage, comfort, and security. The products are designed for easy installation and user-friendly operation, featuring a cohesive aesthetic that complements home decor. By utilizing high-quality electronics and local manufacturing, Wattio ensures that its products are both affordable and reliable, providing consumers with maximum comfort while minimizing energy consumption.

Xagenic Inc., a Toronto, Canada-based molecular diagnostics company developing new technology for decentralized, rapid diagnostic testing, and a true point-of-care platform. Our aim is to enable on-demand, near-patient molecular testing, empowering clinicians in making treatment decisions for their patients at the time of the first consultation. This will dramatically improve patient care and reduce health care costs. Xagenic has adapted this technology to permit rapid, enzyme-free detection of nucleic acids from clinical samples. We are commercializing a simple and fully automated technology platform that will enable widespread decentralized diagnostic testing to be performed outside of clinical laboratories. Our team is developing infectious disease tests that will allow the detection of a variety of analytes in situations where rapid test turnaround will provide clinically actionable results.

Xagenic Inc., a Toronto, Canada-based molecular diagnostics company developing new technology for decentralized, rapid diagnostic testing, and a true point-of-care platform. Our aim is to enable on-demand, near-patient molecular testing, empowering clinicians in making treatment decisions for their patients at the time of the first consultation. This will dramatically improve patient care and reduce health care costs. Xagenic has adapted this technology to permit rapid, enzyme-free detection of nucleic acids from clinical samples. We are commercializing a simple and fully automated technology platform that will enable widespread decentralized diagnostic testing to be performed outside of clinical laboratories. Our team is developing infectious disease tests that will allow the detection of a variety of analytes in situations where rapid test turnaround will provide clinically actionable results.

Zymeworks Inc. is a clinical-stage biopharmaceutical company based in Vancouver, Canada, focused on the discovery, development, and commercialization of innovative biotherapeutics for cancer treatment. The company's lead candidates include ZW25, a bispecific antibody undergoing Phase I and II clinical trials for various tumors, including biliary tract and gastroesophageal adenocarcinomas, and ZW49, a bispecific antibody-drug conjugate in Phase I trials for advanced HER2-expressing cancers. Zymeworks employs a computational biotechnology approach, utilizing proprietary molecular modeling and simulation technologies to optimize therapeutic antibodies and other protein-based therapeutics. The company has established strategic partnerships with notable organizations such as Merck, Eli Lilly, and Bristol-Myers Squibb, as well as collaborations aimed at advancing antibody discovery and development. Founded in 2003, Zymeworks is dedicated to addressing unmet medical needs through its advanced therapeutic platforms and integrated drug development capabilities.

Enobia Pharma is a biotechnology company focused on developing innovative therapies for serious genetic bone disorders that currently lack approved treatment options. The company specializes in addressing conditions such as hypophosphatasia (HPP), a rare inherited disorder that affects bone mineralization and can lead to severe complications. By concentrating on these unmet medical needs, Enobia aims to provide effective solutions that improve patient outcomes and quality of life for individuals suffering from these challenging conditions.

Zymeworks Inc. is a clinical-stage biopharmaceutical company based in Vancouver, Canada, focused on the discovery, development, and commercialization of innovative biotherapeutics for cancer treatment. The company's lead candidates include ZW25, a bispecific antibody undergoing Phase I and II clinical trials for various tumors, including biliary tract and gastroesophageal adenocarcinomas, and ZW49, a bispecific antibody-drug conjugate in Phase I trials for advanced HER2-expressing cancers. Zymeworks employs a computational biotechnology approach, utilizing proprietary molecular modeling and simulation technologies to optimize therapeutic antibodies and other protein-based therapeutics. The company has established strategic partnerships with notable organizations such as Merck, Eli Lilly, and Bristol-Myers Squibb, as well as collaborations aimed at advancing antibody discovery and development. Founded in 2003, Zymeworks is dedicated to addressing unmet medical needs through its advanced therapeutic platforms and integrated drug development capabilities.

BeXcom, a privately held corporation founded in 1996, operates a global network of eCommerce hubs in the world's major trading zones. This global transaction infrastructure enables companies and exchanges to conduct business electronically locally or with multiple trading partners around the world. BeXcom's Commerce Service Provider model provides and maintains all the required hardware and software to operate centralized B2B eCommerce solutions for their users. By building on the BeXcom infrastructure, supply chains, vertical markets and market makers can quickly implement or dramatically extend their eCommerce capabilities to cover the complete range of purchasing processes, from RFQ to settlement. BeXcom is the first company to integrate global financial, logistics, and certificate authority services into a global eCommerce infrastructure, ensuring all transactions are safe, secure, and verifiable. BeXcom helps their customers streamline business processes, reduce costs, expand markets and add value to their business by delivering the full potential of B2B eCommerce.